Login
Companies $BFRI
$0.59 +$0.02 (3.79%) After hours
Biofrontera Inc. logo

Biofrontera Inc.

biofrontera-us.com

What Do They Do?

Sells Ameluz, a prescription treatment, and RhodoLED lamps for precancerous skin lesions to dermatology offices and groups.

How Do They Make Money?

The company sells Ameluz directly to physicians, hospitals and other qualified health providers, with sales tied to delivery; lamp sales follow installation, while rentals and evaluation periods bring monthly fees.

FY2025 revenue

Who Are Their Customers?

The company sells directly to dermatology offices and groups through its own U.S. commercial team; dermatologists buy Ameluz and lamps for in-office treatments.

Do Revenues Turn Into Profits?

No. It lost $10.5M in FY2025.

Operating income, FY2025
−27% of revenue
▲ +34% (Loss) vs FY2024 (−$17.2M, −46%)
Net income, FY2025
−25% of revenue
▲ +41% (Loss) vs FY2024 (−$17.8M, −48%)
Free cash flow, FY2025
−32% of revenue
▼ −30% (Loss) vs FY2024 (−$10.3M, −28%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +30%
vs $7M in Q3 FY2025
Net income
▲ +3% (Loss)
vs −$6.6M in Q3 FY2025
  • Sep 14, 2026 FDA approves Ameluz for superficial basal cell carcinoma The approval adds a use of the existing Ameluz and RhodoLED treatment for superficial basal cell carcinoma in adults.

Growing. Revenue grew 73% in 4 years, from $24.1M in FY2021 to $41.7M in FY2025, about 15% a year.

Portfolio narrows to PDT The earlier report described a portfolio that included topical antibiotics for impetigo and highlighted Xepi; the latest centers on Ameluz and RhodoLED for photodynamic treatment, after Xepi's intangible asset was sold.

From licensed sales to U.S. rights The earlier report described sales of licensed products, with licensors responsible for label-extension research; the latest says Biofrontera acquired U.S. rights to Ameluz and RhodoLED and took control of clinical development and manufacturing.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support